Johnson & Johnson’s HIV vaccine fails trial in sub-Saharan Africa
As a result, the so-called “Imbokodo” trial, which began in 2017 and included some 2,600 women between the ages of 18 and 35, will be stopped and participants from Malawi, Mozambique, South Africa, Zambia and Zimbabwe will be informed if they received the vaccine or the placebo